AlgoTx develops novel drugs for complex pain where none is currently approved. The company was founded in 2018 and raised over 15 M€ to date to take its lead program ATX01 through formulation, pharmacology, pre-clinical toxicology and Phase I clinical development. ATX01 is a non-opioid topical treatment for the pain of Peripheral  Neuropathy, entering Phase II in Chemotherapy-Induced Peripheral Neuropathy. ATX01 is able to directly access the target site in the dermis and epidermis and alleviate the afferent pain message, with a favorable safety profile due to its low systemic passage.

Funding : Launching Series B to fund Phase II program and extend it to centers in Europe and the US